This study aimed to develop solid lipid nanoparticles (SLNs) co-loaded with paclitaxel (PAC) and curcumin (CUR) for improved targeting and treatment of lung cancer. The nanoparticles were prepared using high-pressure homogenization and characterized for size, zeta potential, and drug incorporation efficiency. The results showed that PAC-CUR-SLNs had a particle size of 190 nm with high drug incorporation efficiency (>94%). In vitro drug release studies indicated controlled release of PAC and CUR compared to free drug solutions. Cytotoxicity assays demonstrated higher toxicity of PAC-CUR-SLNs than individual drug-loaded SLNs and pure drugs. In vivo studies in BALB/c mice showed a 12-fold reduction in tumor volume and no significant change in body weight, with 82.7% tumor inhibition on day 28, significantly higher than pure drugs and mono-therapies. The co-delivery of PAC and CUR in SLNs exhibited synergistic effects, indicating potential for improved lung cancer treatment. The study also showed that PAC-CUR-SLNs had better stability and reduced toxicity compared to individual drugs. The results suggest that co-loaded SLNs may enhance targeting and efficacy of chemotherapy for lung cancer.This study aimed to develop solid lipid nanoparticles (SLNs) co-loaded with paclitaxel (PAC) and curcumin (CUR) for improved targeting and treatment of lung cancer. The nanoparticles were prepared using high-pressure homogenization and characterized for size, zeta potential, and drug incorporation efficiency. The results showed that PAC-CUR-SLNs had a particle size of 190 nm with high drug incorporation efficiency (>94%). In vitro drug release studies indicated controlled release of PAC and CUR compared to free drug solutions. Cytotoxicity assays demonstrated higher toxicity of PAC-CUR-SLNs than individual drug-loaded SLNs and pure drugs. In vivo studies in BALB/c mice showed a 12-fold reduction in tumor volume and no significant change in body weight, with 82.7% tumor inhibition on day 28, significantly higher than pure drugs and mono-therapies. The co-delivery of PAC and CUR in SLNs exhibited synergistic effects, indicating potential for improved lung cancer treatment. The study also showed that PAC-CUR-SLNs had better stability and reduced toxicity compared to individual drugs. The results suggest that co-loaded SLNs may enhance targeting and efficacy of chemotherapy for lung cancer.